152606-17-2

Basic information

• Product Name: 3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID
• Synonyms: DL-3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID;3-(2,4-DICHLOROPHENYL)-BETA-ALANINE;3-AMINO-3-(2,4-DICHLOROPHENYL)PROPANOIC ACID;3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID;RARECHEM AK HW 0011;VITAS-BB TBB000139
• CAS NO: 152606-17-2
• Molecular Formula: C9H9Cl2NO2
• Molecular Weight: 234.08
• Product Categories: B-Amino
• Mol File: 152606-17-2.mol

Chemical Properties

• Boiling Point: 371.1°Cat760mmHg
• Flash Point: 178.3°C
• Appearance: /
• Density: 1.447g/cm³
• Vapor Pressure: 3.64E-06mmHg at 25°C
• Refractive Index: 1.6
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID(152606-17-2)
• EPA Substance Registry System: 3-AMINO-3-(2,4-DICHLORO-PHENYL)-PROPIONIC ACID(152606-17-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 152606-17-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
3-Amino-3-(2,4-Dichloro-phenyl)-propionic Acid is used as a research compound for studying its chemical properties and potential interactions with biological systems. Its unique structure, which includes both amino and carboxylic acid functional groups, as well as a 2,4-Dichloro-phenyl component, makes it an interesting subject for scientific investigation.
Used in Pharmaceutical Industry:
3-Amino-3-(2,4-Dichloro-phenyl)-propionic Acid is used as an intermediate compound in the synthesis of more complex pharmaceutical structures. Its functional groups and the presence of chlorine atoms on the phenyl ring may contribute to the development of new drugs with specific therapeutic properties.
Used in Manufacturing Processes:
3-Amino-3-(2,4-Dichloro-phenyl)-propionic Acid is used as a key component in the production of various chemical products. Its reactivity and the influence of its functional groups may be harnessed to create new materials with desired properties for use in different industries.

InChI:InChI=1/C9H9Cl2NO2/c10-5-1-2-6(7(11)3-5)8(12)4-9(13)14/h1-3,8H,4,12H2,(H,13,14)

Upstream product

• 141-82-2 malonic acid 
• 874-42-0 2,4-dichlorobenzaldeyhde 

Relevant articles and documents

Preparation and application of novel eEF2K depressant

The invention relates to preparation and application of an eEF2K depressant and belongs to the technical field of antitumor pharmacy. A technical problem to be solved by the invention is to provide acompound as the eEF2K depressant. The compound comprises a compound represented by a formula shown in the description or pharmaceutically acceptable salts thereof. The compound or pharmaceutically acceptable salts thereof can serve as the eEF2K depressant, have certain anti-tumor activity and can effectively depress the growth of cancer cells. The compound disclosed by the invention has an obviousdepression action on a variety of tumor cells, particularly three-negative mammary cancer cells.

Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase. eEF2K has been recently reported to be highly activated or overexpressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (21l) with best eEF2K enzymatic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM). Moreover, we found that 21l could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells. Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo. These results suggested that 21l inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436). Collectively, our results demonstrate a novel small-molecule inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.